MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$231,750,000
EPS
-$0.31
Unit: Dollar

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Revenue
---0
Research and development
131,096,000 208,021,000 51,265,000 41,127,500
Acquired in-process research and development
0 0 -3,751,750
General and administrative
103,115,000 360,416,000 15,586,000 14,437,000
Impairment of intangible assets
---6,502,750
Total operating expenses
234,211,000 568,437,000 66,851,000 65,819,000
Other operating income, net
---205,000
Operating loss
----65,614,000
Other income, net
2,418,000 2,729,000 3,938,000 13,097,000
Interest expense
0 0 0 2,171,500
Net loss
-231,793,000 -565,708,000 -62,913,000 -61,203,000
Foreign currency translation adjustments
43,000 -189,000 -145,000 135,000
Reclassification of unrealized loss on short-term investments to other expense, net
0 0 -0
Reclassification of cumulative currency translation gain to other expense, net
---0
Unrealized gain (loss) on short-term investments
0 0 -133,000 -100,500
Comprehensive loss
-231,750,000 -565,897,000 -63,191,000 -61,280,000
Basic (in dollars per share)
-0.31 -0.76 -0.09 -0.08
Basic (in shares)
743,415,917 742,615,007 738,076,003 -1,417,804,042
Diluted (in dollars per share)
-0.31 -0.76 -0.09 -0.08
Diluted (in shares)
743,415,917 742,615,007 738,076,003 -1,417,804,042
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$231,750,000 Foreign currencytranslation adjustments$43,000 Net loss-$231,793,000 Other income, net$2,418,000 Total operatingexpenses$234,211,000 General andadministrative$103,115,000 Research and development$131,096,000

summitplc-logo_05fd32df-svg

Summit Therapeutics Inc. (SMMT)

summitplc-logo_05fd32df-svg

Summit Therapeutics Inc. (SMMT)